The Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM).
Launched by NANJING FIRST HOSPITAL, NANJING MEDICAL UNIVERSITY · Sep 18, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, called the Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM), aims to better understand how patients with Type 1 Diabetes are being treated and how their bodies are managing their blood sugar levels. The study will involve 1,000 participants and will look at various aspects, including medical histories, physical exams, questionnaires, and special tests like continuous glucose monitoring and ultrasound of fat tissue. The goal is to identify what factors might influence blood sugar control and to evaluate how effective continuous glucose monitoring systems are for patients in China.
To participate, individuals must have Type 1 Diabetes and be able to provide consent for the study. Key eligibility criteria include having experienced a severe initial diabetes episode, having certain autoantibodies in their blood, or having very low levels of C-peptide, which is a marker of insulin production. Unfortunately, those with other types of diabetes or who cannot cooperate with the monitoring and data collection will not be able to join. Participants can expect to share information about their health and undergo a few tests, contributing to important research that could improve diabetes care for others.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Volunteer to participate and be able to sign informed consent
- • Patients with type 1 diabetes
- • At least one of the following three clinical characteristics must be met: The disease presents initially with diabetic ketoacidosis (DKA) or ketonuria; The presence of islet-related autoantibodies, such as islet cell antibodies, tyrosine phosphatase antibodies, or glutamic acid decarboxylase (GAD) antibodies, is detected positively; Both fasting and postprandial C-peptide levels are ≤0.6 ng/mL.
- Exclusion Criteria:
- • Other types of diabetes.
- • Patients who cannot cooperate with the use of continuous glucose monitoring, clinical data collection, and questionnaire completion.
About Nanjing First Hospital, Nanjing Medical University
Nanjing First Hospital, affiliated with Nanjing Medical University, is a leading medical institution dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on patient-centered care and cutting-edge medical practices, the hospital serves as a key player in the development of new therapies and treatment protocols. Its collaborative environment fosters interdisciplinary research, enabling the integration of scientific inquiry with clinical application. Nanjing First Hospital is committed to improving health outcomes and contributing to the global medical community through rigorous trial design and execution, ensuring the highest standards of ethical practice and patient safety.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Xi'an, Shanxi, China
Beijing, Beijing, China
Fuzhou, Fujian, China
Wuhan, Hubei, China
Xuzhou, Jiangsu, China
Hefei, Anhui, China
Wuxi, Jiangsu, China
Chongqing, Chongqing, China
Chongqing, Chongqing, China
Nanchang, Jiangxi, China
Zhengzhou, Henan, China
Suzhou, Jiangsu, China
Shenyang, Liaoning, China
Shenyang, Liaoning, China
Nantong, Jiangsu, China
Lianyungang, Jiangsu, China
Anqing, Anhui, China
Xi'an, Shanxi, China
Lanzhou, Gansu, China
Shanghai, Shanghai, China
Qingdao, Shandong, China
Linyi, Shandong, China
Beijing, Beijing, China
Jining, Shandong, China
Liaocheng, Shandong, China
Xinxiang, Henan, China
Wuhan, Hubei, China
Qinhuangdao, Hebei, China
Zhengzhou, Henan, China
Zhengzhou, Henan, China
Ha'erbin, Heilongjiang, China
Jilin, Jilin, China
Baoji, Shanxi, China
Xinjiang, Xinjiang, China
Zunyi, Guizhou, China
Jingzhou, Hubei, China
Ha'erbin, Heilongjiang, China
Nanjing, Jiangsu, China
Zhoukou, Henan, China
Guangxi, Guangxi, China
Hefei, Anhui, China
Ha'erbin, Heilongjiang, China
Binzhou, Shandong, China
Bengbu, Anhui, China
Guangzhou, Guangzhou, China
Xinjiang, Xinjiang, China
Qinzhou, Guangxi, China
Rizhao, Shandong, China
Zibo, Anhui, China
Hefei, Anhui, China
Wuhu, Anhui, China
Beijing, Beijing, China
Chongqing, Chongqing, China
Chongqing, Chongqing, China
Fuzhou, Fujian, China
Quanzhou, Fujian, China
Xiamen, Fujian, China
Xiamen, Fujian, China
Xiamen, Fujian, China
Gansu, Gansu, China
Guangxi, Guangxi, China
Guangxi, Guangxi, China
Guangxi, Guangxi, China
Yulin, Guangxi, China
Guangdong, Guangzhou, China
Guangzhou, Guangzhou, China
Guangzhou, Guangzhou, China
Guangzhou, Guangzhou, China
Guangzhou, Guangzhou, China
Anshun, Guizhou, China
Guiyang, Guizhou, China
Guizhou, Guizhou, China
Shijia Zhuang, Hebei, China
Shijia Zhuang, Hebei, China
Tangshan, Hebei, China
Haerbin, Heilongjiang, China
Nanyang, Henan, China
Xinxiang, Henan, China
Zhengzhou, Henan, China
Zhumadian, Henan, China
Jingmen, Hubei, China
Nanjing, Jiangsu, China
Gannan, Jiangxi, China
Jilin, Jilin, China
Jilin, Jilin, China
Neimeng, Neimenggu, China
Neimeng, Neimenggu, China
Yinchuan, Ningxia, China
Qinghai, Qinghai, China
Shanghai, Shanghai, China
Weinan, Shanxi, China
Yulin, Shanxi, China
Chengdu, Sichuan, China
Chengdu, Sichuan, China
Xinjiang, Xinjiang, China
Xinjiang, Xinjiang, China
Xinjiang, Xinjiang, China
Xinxiang, Xinjiang, China
Yunnan, Yunnan, China
Yunnan, Yunnan, China
Patients applied
Trial Officials
Jianhua Ma, Doctor
Study Chair
The First Affiliated Hospital with Nanjing Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported